Overview of Selank
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analogue of tuftsin, a natural tetrapeptide (Thr-Lys-Pro-Arg) with immunomodulatory properties, extended with the Pro-Gly-Pro sequence to enhance metabolic stability. Selank's research profile spans neurological, immunological, and anxiolytic domains, with the GABA-A receptor system and enkephalin-degrading enzymes being the primary investigated pharmacological targets.
GABA-A Receptor Modulation
GABA (γ-aminobutyric acid) is the primary inhibitory neurotransmitter in the mammalian central nervous system. GABA-A receptors are ligand-gated chloride channels; their positive modulation enhances inhibitory tone. Radioligand binding studies with recombinant GABA-A receptor subunits have shown that Selank displaces [3H]-flunitrazepam from the benzodiazepine binding site at micromolar concentrations, indicating a functional interaction at the benzodiazepine modulatory site. Electrophysiology data from Xenopus oocyte expression systems confirmed that Selank potentiates GABA-evoked chloride currents, consistent with a positive allosteric modulator mechanism rather than a direct GABA mimetic.
Enkephalinase Inhibition
Enkephalins are endogenous opioid pentapeptides rapidly degraded by enkephalinase (neprilysin, NEP). In cell-free enzyme inhibition assays, Selank acts as an inhibitor of enkephalinase activity (IC50 ~2 μM vs. Leu-enkephalin substrate), which would be predicted to extend enkephalin half-life in neural tissue. This mechanism is thought to contribute to the anxiolytic profile observed in animal models by potentiating endogenous opioid tone without direct opioid receptor agonism. However, the physiological relevance of this IC50 in cellular contexts requires careful consideration given the concentrations achievable in cell culture models.
Neurotrophin Expression
In common with Semax, Selank has been reported to influence neurotrophin expression in glial and neuronal cell models. Studies from Russian research groups have reported increases in BDNF and NGF mRNA in cortical cell cultures after Selank treatment. Whether this effect is mechanistically related to GABA-A modulation or represents an independent pathway remains unclear. Cross-pathway interactions between GABAergic signalling and neurotrophin expression have been described in the literature and could provide a unifying mechanism, though direct evidence in the context of Selank specifically is limited.
Immunomodulatory Properties
As a tuftsin derivative, Selank retains some of the immunological properties of its parent peptide. Tuftsin binds to a specific receptor on macrophages, monocytes, and polymorphonuclear leukocytes, stimulating phagocytic activity and cytokine production. In macrophage cell culture experiments, Selank has been shown to modulate cytokine profiles, decreasing IL-6 and TNF-α under LPS-stimulated conditions while increasing IL-4, shifting the balance towards an anti-inflammatory phenotype. These immunomodulatory effects are distinct from the GABAergic mechanisms and suggest Selank acts on multiple cell types.